ClinicalTrials.gg
Active, not recruitingNCT06048718TUXEDO-4Updated May 8, 2026

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

A Phase 2 interventional study of Trastuzumab-Deruxtecan (T-DXd) in Breast Cancer and Metastatic Breast Cancer, sponsored by MedSIR. Active, not recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by MedSIR · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms — 32 open to participants now, 46 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
51st of 59
28 · median 138
Started
2024
with 7 others
Phase 2
34 of 59
24 open now
Primary completion
2026-11
later than 13 of 45 live
Registered
28th of 59
by date
Lead sponsor
4 of 59
MedSIR

Among the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 51st largest by enrollment, is one of 8 that started in 2024, is one of 34 in phase 2, reaches primary completion later than 13 of the 45 other live ones, and was the 28th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

TUXEDO-4 is an international, multicentric, single arm, phase II study aiming to gather additional solid evidence of Trastuzumab-Deruxtecan (T-DXd) activity in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-low breast cancer with active brain metastases.

This study will analyze the efficacy of T-DXd as determined by overall response rate (ORR) at any timepoint as judged by best CNS response according to RANO-BM criteria.

Read the detailed description

This is an international, multicentric, single arm, phase II study to evaluate the safety and efficacy of T-DXd in HER2-low breast cancer with newly diagnosed or progressing brain metastases with or without untreated type II leptomeningeal disease (LMD).

Upon meeting all selection criteria, a total of 27 patients will be enrolled as follows: 13 patients will be accrued in stage 1 to receive T-DXd and additional 14 patients will be accrued in stage 2 according to the number of responses seen in stage 1.

The main objective is to analyze the efficacy of T-DXd as determined by ORR at any timepoint as judged by best CNS response according to RANO-BM criteria.

End of study (EoS) will occur 11 months after the last patient included in the Study initiates T-DXd treatment, unless premature termination of the Study. EoS is defined as the last data point at the last participant's visit and will occur after the Study treatment termination of the last patient in the Study.

03

Conditions studied

  • Breast Cancer
  • Metastatic Breast Cancer

Keywords

  • breast cancer
  • HER2-low
  • brain metastases
  • T-DXd
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be capable to understand the purpose of the Study and have signed written form (ICF) prior to beginning specific protocol procedures.
  2. Female or male patients ≥ 18 years of age at the time of signing ICF.
  3. Radiologically documented breast cancer with locally documented -low status according to the 2018 ASCO/CAP guidelines.
  4. ≥ 12 weeks.
  5. (ECOG) performance status (PS) 0-2.
  6. Participants with to T-DXd therapy cannot be enrolled to the Study.
  7. Newly diagnosed or progressive BM without indication for immediate local therapy.
  8. Presenting with ≥1 brain lesion (≥10 mm per local radiological assessment), by Response Assessment in Neuro-Oncology (RANO-BM) criteria. Note: Patients may or may not have untreated type II LMD per European Association of Neuro-Oncology (EANO)- European Society for Molecular Oncology (ESMO) criteria.
  9. Patients must have undergone ≥1 in the advanced setting.
  10. Patients have adequate treatment before enrolment, defined as:

    • local therapy (major surgery and radiotherapy) or antibody treatment ≥4 weeks;
    • targeted agents, chemotherapy, small molecule, or anti-cancer hormonal therapy ≥3 weeks.
  11. Patients must have (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before enrolment.
  12. Patient has adequate bone marrow, liver, renal and coagulation function.

    • Hematological: without , red blood cell transfusion, and/or granulocyte colony-stimulating factor support within 7 days before first Study treatment dose.
    • Hepatic: Serum albumin ≥ 2.5 g/dL; total ≤ 1.5 times (ULN) (≤ 3 in patients with liver metastases or known history of Gilbert's disease); alkaline phosphatase (ALP) ≤ 2.5 times ULN; (AST) and alanine transaminase (ALT) ≤ 3 times ULN; (INR) \< 1.5. Note: ALP, ALT and AST can be ≤ 5 times ULN in patients with liver metastases.
    • Renal: serum creatinine ≤ 1.5 x ULN or ≥ 50 mL/min/1.73 m2 based on Cockcroft-Gault estimation for patients with creatinine levels above institutional normal.
  13. Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as determined by the US National Cancer Institute (NCI)- (CTCAE) version 5.0 (v.5.0). Participants with chronic Grade 2 toxicities may be eligible per the discretion of the investigator. Note: Except for alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion.
  14. For women of : agreement to remain abstinent (must refrain from heterosexual intercourse) or use highly effective methods, or two effective contraceptive methods, as defined in the CSP, during the treatment period and for at least 7 months after the last dose of Study treatment, whichever is longer. Women of childbearing potential must have a negative serum pregnancy test within 14 days before Study treatment initiation and must agree to refrain from donating eggs during the entire Study treatment period and for 7 months after the last administration of the Study drug.
  15. Being male subjects, surgically sterile or having agreed with true abstinence (must refrain from heterosexual intercourse), or whose female partners are willing to agree with true abstinence or use barrier contraceptive measures mentioned above during the entire Study treatment period and for 4 months after the last administration of the Study drug. Males must agree to refrain from donating sperm during the entire Study treatment period and for 4 months after the last administration of the Study drug.
  16. Patients must be able to tolerate therapy.
  17. Patients must be accessible for treatment and follow-up.

Exclusion criteria

Exclusion criteria:

  1. Current participation in another therapeutic clinical trial.
  2. Treatment with approved or cancer therapy such as antibody treatment within 4 weeks prior to initiation of Study drug; or targeted agents, chemotherapy, small molecule, or anti-cancer hormonal therapy within 3 weeks prior to initiation of Study drug.
  3. Patients have a concurrent or malignancy within five years of Study enrolment with the exception of carcinoma in situ of the cervix, non-melanoma skin carcinoma, stage I uterine cancer or contralateral breast cancer within the last 3 years. For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required.
  4. Prior treatment with T-DXd.
  5. Patients with type I LMD or previously treated type II LMD.
  6. Known allergy or to T-DXd or any of the drug components.
  7. Medical history of myocardial infarction (MI) within 6 months before enrolment, symptomatic congestive heart failure ( Class II to IV).
  8. \< 50% as determined by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days prior to treatment.
  9. Long corrected interval prolongation to > 470 ms based on average of screening 12-lead (ECG).
  10. History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required , current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  11. Lung criteria:

    1. Lung-specific intercurrent illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of Study enrolment, severe asthma, severe , restrictive lung disease, etc).
    2. Any , connective tissue or inflammatory disorders (ie, rheumatoid arthritis, Sjogren's, sarcoidosis, etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the eCRF for participants who are included in the Study.
    3. Prior pneumonectomy.
  12. Pregnant or lactating women.
  13. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the Study.
  14. Current known infection with virus (HBV), or virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  15. Known (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, ≥ 350, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended.
  16. History of a major surgical procedure (defined as requiring general anesthesia) or significant traumatic injury within 21 days prior to enrolment, or patients who have not recovered from the side effects of any major surgery.
  17. A history of uncontrolled seizures, central nervous system (CNS) disorders or serious and/or unstable pre-existing psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to Study drugs or interfering with subject safety.
  18. Patients requiring concomitant use of chronic systemic (intravenously [IV] or oral) corticosteroids or other medications except for managing adverse events (inhaled steroids or intra articular steroid injections are permitted in this Study). Corticosteroids (dexamethasone at 4 mg or equivalent doses) are allowed only for the treatment of bone or perifocal oedema and for the treatment of specific adverse drug reactions. The use of ≥ 4 weeks of stable corticosteroid therapy (4 mg/day) in patients with BM can be discussed with the Medical Monitor. Note: Hematopoietic growth factors may be used for prophylaxis or treatment based on the clinical judgment of the investigator. Concomitant use of dietary supplements, medications not prescribed by the Investigator, and alternative/complementary treatments is discouraged, but not prohibited. Prophylactic or supportive treatment of Study-drug induced adverse events will be otherwise as per investigator's discretion and institutional guidelines.
  19. Patients with known substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical Study or evaluation of the clinical Study results.
  20. Use of concurrent investigational agents, endocrine treatments, or other concomitant anti-cancer therapies.
  21. Participants who are unable or unwilling to comply with the requirements of the protocol in the opinion of the investigator.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    T-DXd

    Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion every three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or discontinuation from the study.

    Drug: Trastuzumab-Deruxtecan (T-DXd)

Interventions

  • DrugTrastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.

    Also known as: DS-8021a, ENHERTU

06

What researchers measure

Primary outcomes

  1. ORR at any time point as judged by best central nervous system (CNS) response in all patients.

    To assess efficacy, defined as overall response rate (ORR) at any timepoint as judged by best CNS response according to RANO-BM criteria.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

Secondary outcomes

  1. ORR as judged by best response for extracranial (EC) and overall lesions in all patients.

    ORR for EC and overall lesions, defined as the rate of patients with complete response (CR) or partial response (PR), determined locally by the investigator per RECIST criteria v.1.1.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  2. Bicompartmental clinical benefit rate (Bi-CBR) in all patients.

    Bi-CBR defined as the sum of CR rate, PR rate and more than 24 weeks stable disease (SD) rate, and determined locally by the investigator through the use of RANO-BM criteria for intracranial (IC) lesions and RECIST v.1.1 for EC and overall lesions.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  3. Bicompartmental disease control rate (Bi-DCR) in all patients.

    Bi-DCR, defined as CR+PR+SD, determined locally by the investigator per RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both EC and overall lesions.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  4. Time to response (TTR) in all patients.

    TTR, defined as the period from the treatment initiation to time of the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR, as per RANO-BM for intracranial lesions and RECIST v.1.1 for extracranial and overall lesions.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  5. Duration of response (DoR) in all patients.

    DoR, defined as the period from the first occurrence of a documented objective response to disease progression or death from any cause, observed for patients who achieved a CR or PR, as per RANO-BM for intracranial lesions and RECIST v.1.1 for extracranial and overall lesions.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  6. Best percentage of change in tumor burden in all patients.

    Best percentage of change in tumor burden as per RANO-BM for intracranial lesions and RECIST v.1.1 for extracranial and overall measurable lesions.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  7. Progression-free survival (PFS) in all patients.

    PFS, defined as the period from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first. Progression will be determined locally per RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both EC and overall lesions.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  8. Overall survival (OS) in all patients.

    OS, defined as the period from treatment initiation to death from any cause, determined locally by the investigator.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  9. Incidence of Adverse Events [Safety and Tolerability]

    To evaluate incidence and severity of adverse events, with severity determined in accordance to NCI-CTCAE v.5.0

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  10. Evaluation of the quality of life (QoL) in all patients (QLQ-c30 questionnaire).

    Assessment of QoL with the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-c30). Changes from baseline is fitted to a repeated measures model including subjects as a random effect, baseline, and post-baseline evaluations. Time to Improvement and Deterioration Analysis Using a threshold value for improvement and deterioration specific to the measures of interest, time to improvement and time to deterioration could be estimated. Distributions of time-to-event variables will be estimated using the Kaplan-Meier method. Median times to event with 2-sided 95% confidence intervals will be estimated.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  11. Evaluation of the quality of life (QoL) in all patients (QLQ-BN20 questionnaire).

    Assessment of QoL with the brain cancer specific questionnaire (QLQ-BN20 ). Changes from baseline is fitted to a repeated measures model including subjects as a random effect, baseline, and post-baseline evaluations. Time to Improvement and Deterioration Analysis Using a threshold value for improvement and deterioration specific to the measures of interest, time to improvement and time to deterioration could be estimated. Distributions of time-to-event variables will be estimated using the Kaplan-Meier method. Median times to event with 2-sided 95% confidence intervals will be estimated.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  12. Evaluation of the quality of life (QoL) in all patients (QLQ-BR45 questionnaire).

    Assessment of QoL with the BC specific questionnaire (QLQ-BR45). Changes from baseline is fitted to a repeated measures model including subjects as a random effect, baseline, and post-baseline evaluations. Time to Improvement and Deterioration Analysis Using a threshold value for improvement and deterioration specific to the measures of interest, time to improvement and time to deterioration could be estimated. Distributions of time-to-event variables will be estimated using the Kaplan-Meier method. Median times to event with 2-sided 95% confidence intervals will be estimated.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

  13. Evaluation of neurologic function in all patients.

    To evaluate the neurologic function with clinician-reported outcome Neurologic Assessment in Neuro-Oncology (NANO) scale. The NANO is an objective clinician-reported outcome of neurologic function that consists of 9 neurologic domains: gait, strength, ataxia (upper extremity), sensation, visual fields, facial strength, language, level of consciousness, and behavior. Each domain is subdivided into 3 or 4 levels of function with scores based on discrete quantifiable measures. Levels of function for each domain range from 0 to 2 or 0 to 3. A score of 0 indicates normal function, while the highest score indicates the most severe level of deficit for that domain.

    Time frame: From baseline until approximately 11 months after the last patient included in the study starts treatment.

07

Study locations

13 sites
08

References and documents

Publications

  • Marhold M, Vaz Batista M, Blancas I, Morales C, Saura-Manich C, Saavedra C, Ruiz-Borrego M, Cortez P, Slebe F, Campolier M, Santos JC, Guerrero-Martinez JA, Jimenez-Cortegana C, Rottenmanner B, Forstner H, Bartsch R, Preusser M. TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases. Future Oncol. 2025 Apr;21(9):1065-1073. doi: 10.1080/14796694.2025.2470604. Epub 2025 Feb 28. PubMed 40018758 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 29 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 21, 2023
StartActual
Jun 5, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06048718
Lead sponsor
MedSIR
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jun 5, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
May 8, 2026

Study contacts

Maximilian Marhold, MD, PhD, PD
principal investigator · Medical University of Vienna, Vienna General Hospital, Vienna, Austria
Matthias Preusser, MD, Prof
principal investigator · Medical University of Vienna, Vienna General Hospital, Vienna, Austria

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion